GlassScriptPhysician profile
Siddharth Jayant Kunte
NPI 1639585870
$31,396.55
in general payments reported to CMS, 2019-2025
53 companies · $6,969 in 2025
The $6,969 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.99 · 2020: $99.95 · 2022: $263 · 2023: $44.05 · 2024: $24K · 2025: $6,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,760 · Food and Beverage: $6,071 · Travel and Lodging: $3,792 · Education: $73.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,277.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,760.00 |
| Food and Beverage | $6,071.04 |
| Travel and Lodging | $3,792.17 |
| Education | $73.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $11,419.22 | 2024-2025 | |
| Gilead Sciences, INC. | $9,944.64 | 2024-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $2,458.89 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,160.66 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $1,092.64 | 2025 | |
| Daiichi Sankyo INC. | $828.39 | 2025 | Vanflyta, Enhertu, Datroway |
| Janssen Biotech, INC. | $294.08 | 2024-2025 | Rybrevant, Carvykti, Talvey |
| E.R. Squibb & Sons, L.L.C. | $290.62 | 2025 | Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $281.34 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Foundation Medicine, INC. | $242.59 | 2022 | |
| Incyte Corporation | $241.61 | 2025 | Jakafi, Zynyz, Monjuvi |
| Pfizer INC. | $208.06 | 2025 | |
| Astellas Pharma US INC | $191.98 | 2019-2025 | Vyloy, Xospata |
| Celgene Corporation | $153.72 | 2025 | Reblozyl |
| Exelixis INC. | $144.73 | 2022-2025 | Cabometyx |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siddharth Kunte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.